SQ29548

SQ29548 is a potent, highly selective, and high-affinity antagonist of the thromboxane A2 (TXA2) / prostaglandin H2 (PGH2) receptor (TP receptor). Developed by Bristol Myers Squibb, SQ29548 acts as an inverse agonist at the TP receptor, blocking TXA2-mediated platelet aggregation, vasoconstriction, and bronchoconstriction. It has been widely utilized as a pharmacological research tool to study prostaglandin signaling, vascular tone, and platelet activation. Preclinical studies have also investigated its potential in preventing myocardial ischemia, thrombosis, and breast cancer metastasis by blocking TP-mediated tumor cell extravasation and migration. Although evaluated in preclinical models for ischemic heart disorders and thrombosis, its clinical development was discontinued.

Other names

(5Z)-7-[(1S,2R,3R,4R)-3-[[2-[(phenylamino)carbonyl]hydrazinyl]methyl]-7-oxabicycloheptan-2-yl]-5-heptenoic acid7-[3-[[2-(phenylcarbamoyl)hydrazinyl]methyl]-7-oxabicycloheptan-2-yl]hept-5-enoic acid